Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | -0.07 | 0.19 | 0.06 |
| FCF Yield | 10.96% | 11.89% | 2.89% | 2.10% |
| EV / EBITDA | 7.39 | 9.11 | 31.92 | 8.22 |
| Quality | ||||
| ROIC | 10.87% | 9.97% | -2.39% | 7.25% |
| Gross Margin | 57.01% | 59.18% | 59.52% | 58.81% |
| Cash Conversion Ratio | 1.68 | 2.73 | -2.48 | 1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.44% | 4.28% | 3.79% | 3.30% |
| Free Cash Flow Growth | -12.42% | 393.37% | 23.10% | -32.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.00 | -1.17 | -1.68 | -0.95 |
| Interest Coverage | 17.26 | 14.47 | -2.06 | 29.68 |
| Efficiency | ||||
| Inventory Turnover | 2.50 | 2.85 | 2.87 | 2.95 |
| Cash Conversion Cycle | 122.97 | 108.41 | 122.11 | 123.07 |